Clovis Oncology, Inc. financial data

Industry
Pharmaceutical Preparations
Location
5500 Flatiron Parkway, Suite 100, Boulder, CO
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2022 - Nov 9, 2022

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 56.3 % -66.7%
Quick Ratio 4.73 % -67.9%
Debt-to-equity -222 % +40.9%
Return On Equity 73.7 % -50%
Return On Assets -60.6 % -13.1%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 145M shares +11.5%
Common Stock, Shares, Outstanding 145M shares +13.2%
Common Stock, Value, Issued 145K USD +13.3%
Weighted Average Number of Shares Outstanding, Basic 145M shares +19.3%
Weighted Average Number of Shares Outstanding, Diluted 145M shares +19.3%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 133M USD -14.8%
Costs and Expenses 340M USD -13.8%
Operating Income (Loss) -207M USD +13.2%
Nonoperating Income (Expense) -45.6M USD +25.9%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -252M USD +15.8%
Income Tax Expense (Benefit) -406K USD +26%
Net Income (Loss) Attributable to Parent -252M USD +15.8%
Earnings Per Share, Basic -1.83 USD/shares +35.3%
Earnings Per Share, Diluted -1.83 USD/shares +35.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 58.3M USD -66.1%
Accounts Receivable, after Allowance for Credit Loss, Current 19.5M USD -24.5%
Inventory, Net 11.4M USD -33.9%
Other Assets, Current 7.99M USD -39.4%
Assets, Current 102M USD -55.7%
Property, Plant and Equipment, Net 4.85M USD -32.3%
Intangible Assets, Net (Excluding Goodwill) 56.3M USD -8.7%
Goodwill 63.1M USD 0%
Other Assets, Noncurrent 12M USD -26.2%
Assets 347M USD -31.7%
Accounts Payable, Current 18.1M USD -23.9%
Employee-related Liabilities, Current 14.7M USD -6.57%
Accrued Liabilities, Current 42.5M USD -5.29%
Liabilities, Current 748M USD +564%
Liabilities 765M USD +4.25%
Accumulated Other Comprehensive Income (Loss), Net of Tax -40.9M USD +6.94%
Retained Earnings (Accumulated Deficit) -3.06B USD -8.96%
Stockholders' Equity Attributable to Parent -418M USD -85.3%
Liabilities and Equity 347M USD -31.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -58.5M USD +5.49%
Net Cash Provided by (Used in) Financing Activities 37.9M USD +183%
Net Cash Provided by (Used in) Investing Activities -62K USD +47.5%
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 145M shares +13.2%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -21.2M USD +57%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 58.3M USD -66.1%
Interest Paid, Excluding Capitalized Interest, Operating Activities 3.22M USD -2.07%
Operating Lease, Liability 20.2M USD -15.9%
Payments to Acquire Property, Plant, and Equipment 62K USD -47.5%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -249M USD +16.6%
Lessee, Operating Lease, Liability, to be Paid, Year Two 4.55M USD -2.59%
Lessee, Operating Lease, Liability, to be Paid, Year One 4.86M USD -6.95%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Lessee, Operating Lease, Liability, to be Paid, Year Three 4.7M USD +0.71%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 4.83M USD +0.12%
Operating Lease, Payments 4.96M USD -3.32%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 1.92M USD -14.2%
Share-based Payment Arrangement, Expense 24M USD -21.2%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%